patterns over 3 consecutive years, patterns have been defined as: Persistent Long Quiescent (pLQ), Persistent Relapsing-Remitting (pRR), Persistent Chronic Active (pCA) and Mixed, at least 2 different pattern types. Predictors of pCA (vs. pLQ, pRR and mixed) and pLQ (vs. pCA, pRR and mixed) were identified by univariate and multivariate logistic regression analyses. Several baseline demographics (age, sex, ethnicity, disease duration, tobacco use, years of education and combined annual family income), disease characteristics at baseline (SLEDAI, PGA) and treatment categories (hydroxychloroquine, prednisolone and cytotoxic treatment followed at ≥75% of visits vs <75% of visits) were used as independent variables. Results: 916 patients were identified. The results of the univariate analyses for pCA are shown in table 1. In the multivariate model, African American ethnicity (OR: 2.43, 95% CI: 1.19-4.94, p: 0.01) and high baseline SLEDAI (OR: 1.09, 95% CI: 1.03-1.16, p: 0.004) remained significant predictors of pCA. Higher education (>12 years; OR. 2.16, 95% CI: 1.11-4.20, p: 0.02) and low baseline SLEDAI (OR: 0.62, 95% CI: 0.52-0.75, p:<0.001) were significant predictors of pLQ in the multivariate analysis while African American ethnicity (OR: 0.36, 95% CI: 0.16-0.78, p:0.01) and female patients (OR: 0.26, 95% CI: 0.12-0.56, p:0.001) were less likely to achieve persistent long quiescence. Background: Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). In particular, for aPL carriers (patients with aPL positivity with no thrombotic or obstetric history) pregnancy outcome and treatment are still undefined. Objectives: To review pregnancy outcome in a large multicenter cohort of aPL carriers patients, according to different serological profile and treatment protocols.
Methods:
We reviewed 69 pregnancies in 61 patients, prospectively followed in 3 Italian centers . Patients with any complication in previous pregnancies or concomitant autoimmune diseases were excluded. aPL profile was defined as the combination of the 3 criteria tests for aPL (Lupus Anticoagulant, anti-cardiolipin, anti-Beta2 Glycoprotein I). APO was defined as: miscarriage (<10w), fetal death (≥10w), severe preterm delivery (≤34w) with or without preeclampsia (PE), HELLP syndrome or perinatal death. Results: Regarding aPL profile: 44 (64%) were single positive, 16 (23%) were double and 9 (13%) were triple. aPL non-criteria manifestations were present in 6 (9%) and lupus-like manifestations in 5 (7%). Eight pregnancies had a combination treatment with prophylactic low molecular weight heparin (LMWH) plus low dose aspirin (LDA), 37 had LDA alone and 24 had no treatment. We observed 2 thrombotic events (3%, 1 deep venous thrombosis and 1 ischemic stroke) and 6 APO (9%): 3 fetal deaths and 3 pre-term birth ≤34w with PE. We compared 8 complicated (6 APO,2 thrombosis) with 61 non-complicated pregnancies ( Background: Osteoporotic hip fractures are a significant cause of morbidity and mortality in the elderly. With the aging of the US population, it was expected that there would be a nationwide "epidemic" of osteoporotic fractures; however, Medicare reimbursement for osteoporosis screening and the rapid uptake of bisphosphonate therapy in the late 1990s and early 2000s probably forestalled this epidemic. In fact, osteoporotic hip fractures numbers declined during this time, despite the dramatic growth of the elderly population (1). However, bisphosphonate prescriptions have dropped precipitously by over 50% from their peak in 2008 (2), likely because of concerns regarding their adverse events. In this era of "crisis" in osteoporosis prevention, has the pendulum swung back on hip fracture numbers? Objectives: To study the number and prevalence of osteoporotic hip fractures in patients 50 years and older over the last 22 years in the US? Methods: The Nationwide Inpatient Sample (NIS) is a stratified random sample of all US community hospitals. It is the only US national hospital database with information on all patients, regardless of payer, including persons covered by Medicare, Medicaid, private insurance, and the uninsured. We examined all inpatient hospitalizations in NIS from 1993 to 2014 with a primary diagnosis of non-traumatic hip fractures, and calculated age-adjusted prevalence rates. We excluded patients with concomitant diagnosis of major trauma, primary or secondary tumors locally, osteopetrosis and procedures for revision surgery or surgery for complications. US population estimates and projections for the resident US population were obtained from the US Census Bureau. Results: There were 407 million all-cause hospitalizations in 1.88 billion personyears of observation among people 50 years of older from 1993 to 2014 (21,626 hospitalizations per 100,000 person-years). During this time-period, there were 6.15 million hospitalizations for osteoporotic hip fractures in this population (327 per 100,000 person-years). After an initial increase in hip fractures from 1993 to 1996, there was a decline of 10.6% in total number of hip fractures from 300,154 in 1996 to 268,356 in 2010 even though population of 50 years and older increased from 69.9 million to 99.6 million in the same time. After bottoming out in 2010, the total number of hip fractures increased by 6.2% to 285,050 in 2014 ( Figure, blue broken line) . However, the age-standardized prevalence rate of hip fractures declined steadily (from 414/100,000 in 1996 to 269/100,000 in 2014, p<0.0001, Figure solid red line) , although the rate of decline has ameliorated somewhat from 2010 onwards (not statistically significant).
Conclusions:
The total number of osteoporotic hip fractures in 50 years and older declined since 1996, bottomed out in 2010 but has started increasing again. It is critical to evaluate risks and benefits of preventive treatments for optimal management of this potentially serious problem. Background: Romosozumab (ROMO) inhibits sclerostin and has a dual effect on bone, increasing formation while decreasing resorption, resulting in significant increases in bone mineral density (BMD) at 6 months (m), which at 12m reach 13.3% vs placebo (PBO) at the spine.
1 Using high resolution quantitative computed tomography, BMD increases were observed at both trabecular and cortical compartments of the spine, explaining the significant reductions in radiographic vertebral fracture (VFx) risk in women with osteoporosis (OP) enrolled in the FRAME trial (NCT01575834). Objectives: Here, we report the effect of ROMO on clinical (clin) VFx incidence over 12m in women in FRAME with back pain. Methods: FRAME enrolled 7180 postmenopausal women with OP, mean age 70.9 yrs (total hip T-score -2.5 to -3.5) and no severe VFx. Patients received monthly ROMO (n=3589; 210mg) or PBO (n=3591) for 12m. At monthly visits, women with back pain consistent with a clin VFx had a confirmatory spinal X-ray. Clin VFx risk (ROMO vs PBO) was calculated by Cox-proportional hazards model. Results: Of 119 women reporting back pain over 12m, 20 women were diagnosed with a new or worsening VFx. With ROMO, 3 clin VFx (<0.1%; all at <2m) were identified vs 17 (0.5% at 12m) with PBO ( Figure) . Clin VFx risk was 83% lower in the ROMO group vs PBO at 12m (hazard ratio 0.17; 95% CI, 0.05-0.58; p=0.001). In women with clin VFx vs no clin VFx, the lumbar spine T-score was numerically lower and the FRAX score higher at baseline; other baseline characteristics were comparable among all women who reported back pain.
Conclusions: ROMO treatment for 12m was associated with rapid and large reductions in clin VFx risk vs PBO. In the ROMO group, all clin VFx occurred <2m; clin VFx risk was ≥5 times higher with PBO vs ROMO. Monthly study visits in FRAME allowed for timely radiologic confirmation of a suspected clin VFx.
References:
[1] Cosman F et al. N Engl J Med 2016; 375:1532-43. 
